Background: Pioglitazone ameliorates insulin resistance, but has an adverse effect of oedema that may result in subsequent heart failure, especially in diabetic patients with coronary artery disease. In this study, we evaluated the effects of lowdose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone (RAA) system and natriuretic peptides in diabetic patients with coronary artery disease. Methods and results: We studied 22 diabetic patients with coronary artery disease and more than 40% of left ventricular ejection fraction (LVEF). Patients were treated with 15 mg of pioglitazone for 12 weeks, in addition to their other hypoglycaemic agents. Pioglitazone significantly decreased fasting blood glucose (155.2±52.9 mg/dl to 131.1±38.4 mg/dl, p<0.01) and haemoglobin A1C (7.13±0.44 to 6.69±0.47, p<0.001). It did not affect low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, but significantly decreased triglyceride (115.6±28.8 mg/dl to 99.4±30.0 mg/ dl, p<0.05) and atherogenic index of plasma (0.28±0.17 to 0.19±0.16, p<0.05). Pioglitazone did not affect plasma renin activity, plasma aldosterone, human atrial natriuretic peptide or N-terminal pro-brain natriuretic peptide. Conclusion: Our data suggested that low-dose pioglitazone was a safe and useful agent at least in diabetic patients with coronary artery disease and preserved LVEF.
Introduction
Type 2 diabetes mellitus is a heterogeneous disorder in which insulin resistance represents the core defect along with relative insulin deficiency. 1 Based on the results of recent clinical trials, 2,3 clinicians' interest seems to be focused on curing insulin resistance rather than intensive glucose control. Pioglitazone, peroxisome proliferator-activated receptor-γ agonist, is an oral hypoglycaemic agent which ameliorates insulin resistance to some extent. [4] [5] [6] [7] [8] [9] However, it has an adverse effect of oedema that may result in subsequent heart failure, especially in diabetic patients with coronary artery disease. [10] [11] [12] [13] [14] [15] In this study, we evaluated the effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone (RAA) system and natriuretic peptides in diabetic patients with coronary artery disease.
Methods

Patients
We studied 22 diabetic patients with coronary artery disease and more than 40% of left ventricular ejection fraction (LVEF). Coronary artery disease was defined as more than 75% stenosis in one or more vessels on angiography or history of myocardial infarction or percutaneous coronary intervention. A full medical history was obtained and a complete physical examination was undertaken before inclusion. Patients with anaemia, pretibial oedema, serum creatinine > 1.4 mg/dl or history of bladder cancer were excluded from the study.
Study protocol
Patients were treated with 15 mg of pioglitazone once daily in the morning for 12 weeks, in addition to their other hypoglycaemic agents. The same doses of oral hypoglycaemic agents were continued during the study period. Blood samples were collected before and 12 weeks after the administration of pioglitazone. All blood samples were obtained in the post-absorptive state (nine to 15 h after the last meal). Blood samples were obtained in the morning between 8 a.m. and 11 a.m. after one night of fasting. After 15 minutes of rest in the sitting or spine position, blood was drawn for measurement of glucose, haemoglobin A1C, lipid parameters, plasma renin activity, plasma aldosterone, human atrial natriuretic peptide (hANP) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The atherogenic index of plasma, which correlated inversely with the size of the low-density lipoprotein particle, was calculated as log10 (ratio of triglyceride to high-density lipoprotein cholesterol). 16, 17 Haemodynamic measurements and laboratory tests were performed before and 12 weeks after the treatment with pioglitazone. Informed consent was obtained from all patients.
Analytical procedures
HbA1c was measured by an automated latex immunoagglutination inhibition assay. Plasma renin activity, plasma aldosterone and hANP were determined as described previously. 12, 18 NT-proBNP was measured by immunoassay. 13 C-reactive protein was measured with latex nephelometry.
Statistical analysis
Continuous variables were presented as mean±SD, and categorical variables were presented as percentage frequencies. Statistical analysis was performed with the paired Student's t-test for continuous variables. Differences were considered significant if the p-value was <0.05.
Results
Patient characteristics
Patient characteristics are shown in Table 1 
Effects of pioglitazone on RAA system and natriuretic peptides (Table 2)
Pioglitazone did not affect plasma renin activity (2.80±4.08 ng/ml/hr to 2.60±4.72 ng/ml/hr, p=NS) and plasma aldosterone (9.56±3.68 pg/ml to 9.13±3.76 pg/ml, p=NS). Before the administration of pioglitazone, there was a significant correlation between hANP and NT-proBNP (r=0.62, p<0.01) (Figure 1 ). Changes in hANP and NT-proBNP are shown in Figure 2 . Pioglitazone did not affect hANP (43.6±22.2 pg/ml to 46.5±22.5 pg/ml, p=NS) and NT-proBNP (188.6±162.4 pg/ml to 218.2±173.8 pg/ml, p=NS).
Discussion
This study demonstrated that low-dose pioglitazone decreased fasting blood glucose, haemoglobin A1C and atherogenic index of plasma with no significant change in RAA system and natriuretic peptides in diabetic patients with coronary artery disease and preserved LVEF.
Diabetes plays a major role in the accelerated atherosclerotic process, resulting in increased cardiovascular events. Previous studies have shown that intensive glucose control is effective in preventing microvascular events, but its impact on reducing macrovascular events is less evident in diabetic patients. The PROspective pioglitAzone Clinical Trial in macroVascular Events (PROACTIVE) study demonstrated that pioglitazone resulted in a significant reduction of hard cardiovascular events in patients with diabetes and a history of cardiovascular disease. 7 This study established a specific role for pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes. The Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) study demonstrated that pioglitazone resulted in a significantly lower rate of coronary atherosclerotic progression in diabetic patients compared with glimepiride. 8 Thus, pioglitazone is an attractive oral hypoglycaemic agent, especially in diabetic patients with coronary artery disease. However, it has an adverse effect of an expansion in plasma volume. Kahara et al. previously studied the effects of 15 mg of pioglitazone on hANP in diabetic patients and reported that hANP increased significantly from 19.8 pg/ml to 26.0 pg/ml. 12 Sambanis et al. also studied the effects of 30 mg of pioglitazone on NT-proBNP in diabetic patients and reported that NT-proBNP increased significantly from 51.2 pg/ml to 63.8 pg/ml. 13 There have been few reports assessing its effects on natriuretic peptides in diabetic patients with coronary artery disease who have a higher risk of developing congestive heart failure. In our study, pioglitazone did not affect hANP and NT-proBNP during the study period in spite of higher baseline values compared with those of previous studies. There are several possible reasons for the discrepancy between previous and our studies. First, previous studies reported that thiazolidine-induced oedema was doserelated and occurred most frequently when the thiazolidines were used in combination with insulin. 14 In our study, we used only 15 mg of pioglitazone, which was relatively lower compared to doses of previous studies, and there was no patient receiving insulin therapy. It was noteworthy that this low dose of pioglitazone could decrease fasting blood glucose as well as haemoglobin A1C significantly in diabetic patients with coronary artery disease. Second, thiazolidineinduced oedema is caused by direct renal tubular effect as well as renin secretion. Zanchi et al. previously showed that pioglitazone stimulated plasma renin activity and favoured sodium retention and weight gain in healthy volunteers. 19 In our study, 68% of patients were receiving angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers that inhibited aldosterone secretion, and 64% of patients were receiving β blockers that inhibited renin secretion. Consequently, pioglitazone did not affect plasma renin activity and plasma aldosterone during the study period. These cardioprotective agents may contribute to the prevention of thiazolidine-induced oedema. Amelioration of insulin resistance by pioglitazone is also associated with an increase in high-density lipoprotein cholesterol and a decrease in triglyceride. These effects were found in our study. Our study also demonstrated that pioglitazone did not affect low-density lipoprotein cholesterol, but caused a significant decrease in atherogenic index of plasma, indicating a shift to larger and less atherogenic low-density lipoprotein particles. 16, 17 These effects are also favourable in diabetic patients with coronary artery disease.
Study limitations
There were several limitations in this study. First, we assessed the effect of pioglitazone for 12 weeks, but longterm follow-up data were not obtained. Second, we did not assess the effect of higher doses of pioglitazone. There is a possibility that higher doses of pioglitazone affect RAA system and natriuretic peptides in diabetic patients with coronary artery disease. Third, we did not evaluate other hypoglycaemic factors such as diet, exercise or lifestyle modification. Finally, the small sample size is a major limitation, and a larger study should be performed to confirm our findings.
Conclusion
In conclusion, our data demonstrated that low-dose pioglitazone for 12 weeks significantly decreased fasting blood glucose as well as haemoglobin A1C with no significant change in RAA system and natriuretic peptides in diabetic patients with coronary artery disease and preserved LVEF. Our data suggested that low-dose pioglitazone was a safe and useful agent at least in diabetic patients with coronary artery disease and preserved LVEF.
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